PHARMACY

AAM adopts ethics code for members

BY David Salazar

The Association for Accessible Medicines has established a code of business ethics for its members that manufacture generic drugs and biosimilars. The Washington, D.C.-based generics advocacy organization’s board of directors unanimously adopted the code, which sets up certain ethical and business standards and takes effect Sept. 1.

“The AAM Code of Business Ethics stands out from other pharmaceutical industry codes because of AAM’s clear recognition of the ethical value of access to medicines for patients,” AAM president and CEO Chip Davis said. “Our new code also prioritizes market competition as a driving force. The practices discussed in the AAM code represent behaviors and conduct that AAM companies have been demonstrating for many years.”

Though the AAM said it also endorses such international ethics guidelines as the Asia Pacific Economic Cooperation Mexico City Principles on Voluntary Codes of Business Ethics int he Biopharmaceutical Sector, it noted that some member companies are separate from the global branded drug manufacturer signatories to that framework.

AAM’s ethics code includes general provisions about  guidelines about medicine safety, competition and clinical trials, among other elements, as well as sections about companies’ relationships to healthcare professionals.

“We must never take the ethics of healthcare access for granted,” the ethics code says. “Our companies believe in our ethical mission, and AAM’s Board of Directors has approved this Code. AAM looks forward to working with all stakeholders to expand access to generic and biosimilar medicines — the proven, reliable way to drive down the cost of medicine, which helps patients, strengthens our economy, and benefits our society.”

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Generic Mutamycin launch grows Mylan’s oncology portfolio

BY David Salazar

Mylan recently introduced its generic Mutamycin (mitomycin for injection). The product, indicated to treat stomach and pancreatic cancers in combination with other medicines, grows Mylan’s injectable and oncology portfolios, the Pittsburgh-based company said.

Mylan’s generic Mutamycin will be available in 5- 20- and 40-mg/vial single-dose vial. The company had previously received Food and Drug Administration approval for the product, which had U.S. sales of roughly $59 million for the 12 months ended January 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

iMedicare rebrands as Amplicare

BY David Salazar

Medicare plan comparison software company iMedicare has crafted a new corporate identity alongside revamping and augmenting its pharmacy platform with new tools. The newly dubbed Amplicare said that its platform now includes capabilities beyond Medicare, using patient data to find opportunities where pharmacists can proactively improve patient care.

“There is no change in ownership with the rebranding,” Matt Johnson, COO of New York City-based Amplicare, said. “The same healthcare expert team that is committed to the values of integrity, transparency, and innovation for the empowerment of humanity continue to focus on harnessing structured and unstructured data, presented in user-friendly software interface that enable healthcare providers do what they do best: provide impactful clinical advice and care for their patients.”

The platform now includes Amplicare Connect, which allows pharmacists to create outbound refills in their own voice, as well as Amplicare Restore, which identifies over-the-counter products that a patient might benefit from. Its Amplicare Impact tool that identifies patients who are impacting a pharmacy’s Star Rating measures and Amplicare Assist, which integrates with pharmacy systems to highlight opportunities generated from other Amplicare tools, also now augment the iMedicare plan comparison tool.

“At Amplicare, we work at the intersection of technology and healthcare,” CEO Flaviu Simihaian said. “We are excited about our new brand and continue to use our energy and knowledge to keep breaking down the complex barriers in health care. We strive to make healthcare more open, transparent, and accessible to all.”

The company also offers free webinars to explain the Amplicare platform on its website.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?